INTRODUCTION
Worldwide there is a significant clinical need for a portable instrument to make rapid, accurate, and convenient near-patient measurements of total plasma bilirubin in neonates. Several wellknown trends in the epidemiology and management of neonatal hyperbilirubinemia lead to this conclusion. First, about two thirds of the babies born annually in the United States become clinically jaundiced. 1 Second, the neurologic sequelae of untreated or inadequately managed hyperbilirubinemia can be devastating. Third, management guidelines established by the American Academy of Pediatrics are based on specific quantitative measurements of total bilirubin in blood. 1 Fourth, the appropriate management of patients with neonatal hyperbilirubinemia usually requires repeated measurements of total bilirubin to detect temporal trends such as rising or falling blood levels. Finally, even the in-hospital turn-around time between obtaining a blood sample and receiving results from a central clinical laboratory often slows the pediatrician's management of healthy and hyperbilirubinemic neonates and can delay the discharge of mother and child from the hospital (unnecessarily increasing healthcare costs). Furthermore, hyperbilirubinemia is the most frequent cause (85%) of hospital readmissions in the neonatal period. 2 In our view, a portable bilirubinometer for a supervised home or outpatient follow-up program could reduce the frequency of these readmissions as well as facilitate the in-hospital management of the patient.
BACKGROUND:
Conventional methods for measuring the total bilirubin concentration in blood require the use of serum or plasma, but physically separating red blood cells from plasma by centrifugation is a time -consuming and potentially dangerous process that does not lend itself to rapid, near -patient testing. Therefore, we have sought to determine whether spectrophotometric measurements of total bilirubin concentration are feasible in unaltered whole blood.
METHODS:
We modified an Hb -Quick hemoglobinometer ( Avox Systems, Inc., San Antonio, TX ), a relatively new, portable, battery -powered instrument that uses disposable cuvettes and a reagentless system to measure total hemoglobin in nonhemolyzed, whole blood. The prototype consisted of an Hb -Quick equipped with light -emitting diodes with emissions at five different wavelengths to measure total bilirubin and total hemoglobin. Using blood samples from neonates with suspected hyperbilirubinemia, we made measurements on plasma from centrifuged samples and on hemolyzed and nonhemolyzed aliquots of the same blood samples.
RESULTS:
In the first series of experiments, we compared the Unistat bilirubinometer's readings with the prototype's measurements of bilirubin in plasma. There was a close linear correlation between the prototype's measurements and those of the reference instrument ( slope = 1.01, r 2 = 0.991 ) . Subsequently, we used the prototype's measurements on plasma as the reference method and compared them with readings on hemolyzed and nonhemolyzed aliquots of each sample. Readings on hemolyzed and nonhemolyzed aliquots were significantly correlated with the measurements in plasma, but the regression lines did not have a slope of 1. However, when the measurements on hemolyzed and nonhemolyzed blood were scaled appropriately to compensate for the fact that red cells ''dilute'' the bilirubin in plasma, the correlation coefficients improved, and there was then a 1:1 relationship between the measurements in whole blood and plasma.
CONCLUSIONS:
These preliminary findings demonstrate the feasibility of developing a portable instrument to measure total bilirubin in unaltered whole blood. Original Article
Because of the intense light scattering caused by red blood cells, 3 spectrophotometric measurements of bilirubin in whole blood were previously considered impossible or impractical. In addition, the four major hemoglobin species exist in relatively high concentrations (grams per deciliter) compared with bilirubin (milligrams per deciliter), and their absorbance spectra intertwine with the absorbance spectrum of bilirubin. Consequently, all prior in vitro methods have required physically separating red blood cells from plasma, and the bilirubin measurements were subsequently made in the separated plasma or serum. Ideally, a method for near-patient testing would be fast and would not require any sample preparation or the centrifugation and possible aerosolization of potentially infectious blood samples. Therefore, we have sought to determine whether direct spectrophotometric measurements of total bilirubin concentration are feasible in unaltered whole blood. Preliminary results indicate that the new method achieves clinically acceptable accuracy and could be developed into a portable bilirubinometer for rapidly screening and following up neonates with suspected hyperbilirubinemia.
METHODS

Description of Test Instrument
The prototype bilirubinometer consisted of a modified Hb-Quick hemoglobinometer (Avox Systems, Inc., San Antonio, TX), a relatively new, portable, battery-powered instrument that uses disposable cuvettes and a reagentless system to measure the total hemoglobin concentration in nonhemolyzed, whole blood. 4 Figure 1 shows photographs of the Hb-Quick and the disposable cuvettes it uses.
The prototype bilirubinometer was an Hb-Quick 4 in which lightemitting diodes were installed with emissions at five different wavelengths to measure total bilirubin and total hemoglobin. Because five different wavelengths are employed, the prototype's measurement of total hemoglobin includes the four major hemoglobin species, i.e., oxy-, deoxy-, carboxy-, and methemoglobin. Operating the instrument consists simply of letting a droplet of blood touch the slot in the cuvette, which fills by capillary action, inserting the filled cuvette into the instrument, and shutting the door to the sample chamber. The subsequent analysis takes about 10 to 15 seconds and requires less than 10 l of blood. The results are then shown on a liquid-crystal display and stored in memory.
Study Subjects and Materials
This study was conducted in accordance with a protocol approved by the Institutional Review Board of the University of Texas Health Science Center at San Antonio. Some of the blood was from discarded samples taken from hospital patients for routine diagnostic purposes, and informed consent was not deemed necessary. However, other samples were taken from neonates with suspected hyperbilirubinemia. In these cases, the attending physician had ordered a heel stick and a bilirubin measurement. If the patient's mother gave her informed, written consent, two additional capillary tubes of blood were taken for this study (a total volume of 140 l). Photo on left shows the modified Hb -Quick hemoglobinometer that was used as a prototype bilirubinometer in this study. Photo on right is a magnified view of the disposable cuvettes used by the prototype bilirubinometer (photos courtesy of Avox Systems ) .
In the first series of experiments, the blood samples were collected in heparinized capillary tubes and centrifuged. One aliquot of the plasma was analyzed on a conventional, two-wavelength, bench-top bilirubinometer (Leica Unistat Bilirubinometer, Leica Microsystems, Buffalo, NY). A second aliquot of the plasma was analyzed on the prototype. As discussed later, there was excellent agreement between the prototype's measurements and those of the reference instrument. Therefore, in the second series of experiments, we used the prototype's measurements on plasma as the reference method and compared them with readings on hemolyzed and nonhemolyzed aliquots of each blood sample. In these experiments, the blood samples collected in heparinized capillary tubes were divided into three aliquots, one of which was not altered, one of which was centrifuged to obtain plasma, and one of which was hemolyzed with sodium desoxycholate (Sigma, St. Louis, MO). Hemolyzing one of the aliquots provided a way to reduce the light scattering caused by red blood cells and thus to determine whether hemolysis could be used to improve the accuracy in comparison to the measurements on unaltered whole blood.
RESULTS
In the first series of experiments, we obtained blood samples from 33 patients. We used the Unistat bilirubinometer as the reference method and compared its readings with the prototype's measurements of bilirubin in plasma. The results are shown in Figure 2 . As the figure indicates, there was a close linear correlation between the prototype's measurements and those of the reference instrument (slope=1.01, r 2 =0.991). Furthermore, the mean difference between the prototype's measurements and the Unistat's was only 0.64 mg/dl ±0.53 (SD). The mean difference between the prototype's and the Unistat's measurements in plasma indicates that the bias between the two instruments is only 0.64 mg/dl. If the bias were eliminated by careful calibration and if the error in the Unistat's measurements were negligible, the standard deviation of the differences between the two instruments (0.53 mg/dl) would be an estimate of the prototype's inaccuracy when measuring total bilirubin in plasma. However, the error in the Unistat's measurements is not negligible, so the SD of the differences between the two instruments (0.53 mg/dl) is an estimate of the upper limit of the prototype's inaccuracy when measuring total bilirubin in plasma. For a more complete discussion of the statistical aspects of assessing instrument error, please see Shepherd and McMahan. 5 These statistics from the first series of experiments established that the prototype bilirubinometer's measurements of bilirubin in plasma are comparable to those of the widely used Unistat bilirubinometer.
In the second series of experiments, we obtained blood samples from 35 additional patients. We used the prototype's measurements on plasma as the reference method and compared them with readings on hemolyzed and nonhemolyzed aliquots of each blood sample. The results with nonhemolyzed whole blood are shown in Figure 3 . As the upper panel of Figure 3 shows, there was a highly significant, linear relationship between the bilirubin measurements in plasma and those in nonhemolyzed whole blood. Moreover, the standard error of the estimate was 1.07 mg/dl. However, the relationship was not one to one. In fact, the concentration expressed as the amount of bilirubin per unit volume of whole blood was only about half of the bilirubin concentration expressed as the amount of bilirubin per unit volume of plasma. The reason for this disparity is that red blood cells contain little if any bilirubin even though bilirubin adheres to the red cell membrane. 6, 7 Therefore, the mass of bilirubin-free red blood cells, in effect, dilutes the bilirubin in plasma.
To convert the prototype's measurements into the bilirubin concentration per unit volume of plasma, it is necessary to divide the whole blood concentration by 1ÀHct, where Hct is the fractional hematocrit. Similarly, the whole blood concentration can be multiplied by MCHC/ (MCHCÀ [THb] ), where MCHC and THb are the mean corpuscular hemoglobin concentration and the total hemoglobin concentration, respectively. The derivations of these relationships can be found in the Appendix. Because the prototype measures the total hemoglobin concentration as well as total bilirubin, we used the latter method, i.e., the measured THb and an assumed MCHC of 34 g/dl.
As the lower panel of Figure 4 shows, when the measurements on nonhemolyzed whole blood were rescaled appropriately, the correlation coefficients improved, and there was then a 1:1 relationship between the measurements in whole blood and in plasma. After the data were rescaled in this manner, the mean difference between the measurements in plasma and nonhemolyzed whole blood was 0.67±1.53 mg/dl of bilirubin. The mean difference between the measurements in plasma and nonhemolyzed whole blood indicates that the bias between the two methods is 0.67 mg/dl. If the same assumptions are made that were previously described in regard to the measurements in plasma, the SD of the differences between the two methods (1.53 mg/dl) provides an estimate of the Figure 2 . There was a close 1:1 relationship between the prototype's measurements on plasma and those made on the Unistat Bilirubinometer.
Steinke et al.
Feasibility of Measuring Bilirubin in Whole Blood inaccuracy of the measurements in nonhemolyzed whole blood. In a separate study, we obtained an estimate of the precision of the bilirubin measurements in nonhemolyzed whole blood by taking duplicate readings on each of 30 blood samples. The estimate of the precision was 1.19 mg/dl over a bilirubin range of 0 to 14.8 mg/dl. Although these results with nonhemolyzed whole blood are promising, we also wanted to know whether the accuracy could be improved by hemolyzing the blood samples before analyzing them to reduce the deleterious effects of light scattering on the spectrophotometric measurements. The results of these experiments are shown in Figure 4 . As the upper panel of Figure 4 shows, there was a highly significant, linear relationship between the bilirubin measurements in plasma and those in hemolyzed aliquots of the same blood samples previously shown in Figure 3 . Moreover, the standard error of the estimate was 0.78 mg/dl. As the lower panel of Figure 4 shows, when the measurements on hemolyzed blood were scaled appropriately, the correlation coefficients improved, and there was then a 1:1 relationship between the measurements in hemolyzed blood and in plasma. After the data were rescaled in this manner, the mean difference between the measurements in plasma and hemolyzed blood was 0.88±1.02 mg/dl of bilirubin. The mean difference between the measurements in plasma and nonhemolyzed whole blood indicates that the bias between the two methods is 0.88 mg/dl, whereas the standard deviation of the differences between the two methods (1.02 mg/dl) provides an estimate of the inaccuracy of the measurements in hemolyzed blood. This estimate of the inaccuracy is smaller than the 1.53 mg/dl previously noted with Figure 4 . The prototype's measurements of bilirubin in hemolyzed blood from neonates with suspected hyperbilirubinemia were significantly correlated with measurements made in plasma ( upper panel ) . The same data, when rescaled using the prototype's measurements of total hemoglobin and , showed a 1:1 relationship between the plasma values and those in hemolyzed blood ( lower panel ) . Each data point represents the average of two readings on one patient sample. Figure 3 . The prototype's measurements of bilirubin in nonhemolyzed whole blood from neonates with suspected hyperbilirubinemia were significantly correlated with measurements made in plasma ( upper panel ). The same data, when rescaled using the prototype's measurements of total hemoglobin and , showed a 1:1 relationship between the plasma values and those in nonhemolyzed whole blood (Equation 11 lower panel ). Each data point represents the average of two readings on one patient sample.
nonhemolyzed whole blood. Thus, it can be concluded that hemolysis improved the accuracy. In a separate study, we obtained an estimate of the precision of the bilirubin measurements in hemolyzed whole blood by taking duplicate readings on each of 30 blood samples. The estimate of the precision was 0.72 mg/dl over a bilirubin concentration range of 0 to 14.8 mg/dl.
DISCUSSION
In 1998 we published a preliminary report 8 indicating that it was possible to make semiquantitative measurements of total bilirubin concentration in nonhemolyzed whole blood. The present study extends that work and shows that accurate, quantitative measurements are possible both in hemolyzed and nonhemolyzed blood. Therefore, the present results demonstrate the feasibility of developing a portable bilirubinometer for rapidly screening and following up neonates with suspected hyperbilirubinemia. This new approach offers a number of clinically significant advantages: Only 10 l of blood is needed. No sample preparation or pretreatment is required. No reagents are used, so waiting for chemical reactions is unnecessary. In fact, the measurement takes only 10 to 15 seconds. The optical cuvettes are inexpensive disposables that fill by capillary action, and the portable, battery-powered photometer also measures the total hemoglobin concentration in each blood sample.
A limitation of this new approach is that the bilirubin measurements in whole blood are slightly less accurate than spectrophotometric measurements in plasma (our estimates of the inaccuracy in nonhemolyzed blood, hemolyzed blood, and plasma were ±1.53, 1.02, and 0.53 mg/dl, respectively). However, the device can also measure bilirubin in plasma when greater accuracy is needed, for example, to confirm a value on a clinical borderline. A potential disadvantage is that the measurements on intact and hemolyzed blood yield units of bilirubin per volume of whole blood, whereas the universal clinical convention is to express bilirubin concentration as the amount of bilirubin per volume of serum or plasma. However, as Figures 3 and 4 show, the bilirubin concentration measured directly in whole blood can easily be converted to the conventional plasma concentration, provided either hematocrit or mean corpuscular hemoglobin concentration is known. If the prototype presented here can be developed into the portable bilirubinometer we envisage, its speed, simplicity, low cost, portability, and low maintenance requirements will make it suitable for near-patient testing in newborn nurseries, neonatal intensive care units, other in-hospital settings, home-care programs, and physicians' offices.
However, the amount of bilirubin inside red blood cells is negligible. Thus, Equation 6 becomes
Solving Equation 1 for the amount of bilirubin in plasma and substituting for Bil p in Equation 7 yields
From Equation 3 it can be deduced that the ratio of plasma volume to total blood volume ( V p / V b ) is 1À Hct, so substituting 1 À Hct into Equation 8 gives
and solving for the bilirubin concentration in plasma, we obtain ½Bil p ¼ ½Bil b =ð1 À HctÞ: ð10Þ
Equations 9 and 10 make it readily apparent that the bilirubin concentration in whole blood can be converted into the concentration in plasma ( and vice versa ) , if the hematocrit is known. Similarly, the ratio of total hemoglobin concentration to mean corpuscular hemoglobin concentration ( Equation 5 ) 
